Related references
Note: Only part of the references are listed.Novel thiazole derivatives: a patent review (2008-2012; Part 1)
Alberto Leoni et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Study on integrity and timing characteristics of Shaoyao and Gancao decoction on anti-inflammatory effects by BP neural network
ACTA PHARMACOLOGICA SINICA (2013)
Review article: a comparison of glucagon-like peptides 1 and 2
P. Janssen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Dopamine D3 receptor antagonists: a patent review (2007-2012)
Fabrizio Micheli et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
Anthony H. V. Schapira et al.
LANCET NEUROLOGY (2013)
Sphingosine-1-phosphate signaling in physiology and diseases
Yoh Takuwa et al.
BIOFACTORS (2012)
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Maria P. Menendez-Gutierrez et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2012)
Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature
Craig W. Lindsley et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
5HT6 receptor antagonists: a patent update. Part 1. Sulfonyl derivatives
Alexandre V. Ivachtchenko et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Selective cannabinoid receptor 2 modulators: a patent review 2009-present
Doris Riether
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
5-HT6 receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds
Alexandre V. Ivachtchenko et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present)
Christina Lamers et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Exploring Mechanisms Underlying Extinction of Cue-Elicited Cocaine Seeking
Han Kong et al.
CURRENT NEUROPHARMACOLOGY (2011)
Latest advances in cannabinoid receptor agonists
Ganesh A. Thakur et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Magnetic Resonance Imaging
Betty B. Yao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Neurofibromin Regulation of ERK Signaling Modulates GABA Release and Learning
Yijun Cui et al.
CELL (2008)
Selective 5-HT6 receptor ligands:: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders
D. J. Heal et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Latest advances in the cannabinoids
E. Kate Hoegenauer
EXPERT OPINION ON THERAPEUTIC PATENTS (2007)
The quest for the treatment of cognitive impairment:: α7 nicotinic and α5 GABAA receptor modulators
Maria Novella Romanelli et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2007)
Targeting the α9α10 nicotinic acetylcholine receptor to treat severe pain
Michelle Vincler et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Selective α7 nicotinic acetylcholine receptor ligands for the treatment of neuropsychiatric diseases
Lisa M. Broad et al.
DRUGS OF THE FUTURE (2007)
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats
Angels Fisas et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Adenosine receptors as therapeutic targets
KA Jacobson et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Adenosine A1 receptor antagonist improves intradialytic hypotension
E Imai et al.
KIDNEY INTERNATIONAL (2006)
Brain neuronal nicotinic receptors as new targets for drug discovery
C Gotti et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons
MR D'Andrea et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses
SH Wei et al.
NATURE IMMUNOLOGY (2005)
FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors
K Chiba
PHARMACOLOGY & THERAPEUTICS (2005)
Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network
H Rosen et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine
ZL Huang et al.
NATURE NEUROSCIENCE (2005)
The GABA type A receptor α5 subunit gene is associated with bipolar I disorder
K Otani et al.
NEUROSCIENCE LETTERS (2005)
Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents
AH Newman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Free fatty acids inhibit serum deprivation-induced apoptosis through GPR120 in a murine enteroendocrine cell line STC-1
S Katsuma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
A Hirasawa et al.
NATURE MEDICINE (2005)
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice
M Webb et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Structural and functional characteristics of S1P receptors
T Sanchez et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists
JJ Hale et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging
M Rausch et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2004)
A linkage disequilibrium map of the 1-Mb 15q12 GABAA receptor subunit cluster and association to autism
JL McCauley et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2004)
Nicotinic acetylcholine receptors and the regulation of neuronal signalling
F Dajas-Bailador et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion
PE MacDonald et al.
DIABETES (2002)
International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature
J Chun et al.
PHARMACOLOGICAL REVIEWS (2002)
ATP-gated ion channel P2X3 is increased in human inflammatory bowel disease
Y Yiangou et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2001)
A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze
ML Woolley et al.
NEUROPHARMACOLOGY (2001)
Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors
S Pyne et al.
PHARMACOLOGY & THERAPEUTICS (2000)